Vaximm AG Appoints Dr. Andreas Niethammer as CEO
OSR Holdings, Inc. (NASDAQ: OSRH) has promoted Dr. Andreas Niethammer, the Chief Medical Officer and co-founder of Vaximm AG, to Chief Executive Officer (CEO). This strategic move is effective as the company prepares for an important new phase in its mission to expand immuno-oncology therapies.
Dr. Niethammer, a distinguished figure in oncology, co-founded Vaximm AG based on groundbreaking research conducted at The Scripps Research Institute. His work notably included the development of oral T-cell vaccination methods, a revolutionary concept that was first published in a significant Nature study in 2002. This understanding has led Vaximm to make substantial progress with its leading product, VXM01, a therapeutic vaccine targeting VEGFR-2. The vaccine is currently undergoing first-in-human clinical trials aimed at treating conditions like pancreatic cancer and glioblastoma, showcasing the potential of oral vector-based immunotherapy focused on tumor vasculature.
Pioneering a New Direction in Combination Immuno-Oncology
As Dr. Niethammer steps into this new role as CEO, Vaximm AG will prioritize the integration of its anti-angiogenic immune activation capabilities with exceptional viral oncolytic technologies. These technologies have already been validated through a successful Phase 2a study approved by the U.S. FDA. The forthcoming announcement of a strategic collaboration is said to enhance the development of a next-generation immuno-oncology platform. This platform aims to tap into sophisticated mechanisms to combat renal cell carcinoma (RCC) and other advanced tumors.
Dr. Niethammer expressed his enthusiasm about his new position, stating, "I am honored to take on the CEO role during a thrilling period for Vaximm. Our oral vaccination platform stands ready to merge with powerful oncolytic and immune-modulating strategies. This combination promises to yield significantly durable systemic antitumor responses along with a commendable safety profile."
Peter Hwang, CEO of OSR Holdings, remarked on the significance of Dr. Niethammer's appointment, noting that his unique blend of scientific insight and rich clinical development experience positions Vaximm for exceptional growth. Hwang emphasized that this appointment marks a pivotal moment as the company embarks on the next chapter filled with scientific advancement and strategic partnerships intended to escalate the rollout of cutting-edge therapies.
Understanding Vaximm AG: A Leader in Biotech
Vaximm AG operates as a privately held biotechnology company based in Switzerland and Germany, functioning as a proud subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH). The company’s distinguished oral T-cell vaccination platform utilizes innovative live, attenuated bacterial vectors to convey tumor-associated antigens aiming to ignite robust cellular immune responses. The lead candidate, VXM01, designed to target VEGFR-2, has exhibited promising clinical activity and safety across various cancer types.
OSR Holdings, Inc.: Committed to Health Innovations
OSR Holdings, Inc. (NASDAQ: OSRH) stands as a global entity focused on transforming healthcare by promoting biomedical innovations in health and wellness. Through its array of subsidiaries, OSR Holdings participates actively in fields such as immuno-oncology, regenerative biologics, and medical device technologies, all dedicated to improving health outcomes worldwide.
Frequently Asked Questions
Who is the new CEO of Vaximm AG?
Dr. Andreas Niethammer has been appointed as the new CEO of Vaximm AG.
What are the main focuses of Vaximm AG?
Vaximm AG focuses on developing oral T-cell immunotherapies for various cancers.
What is the lead product of Vaximm AG?
The lead product is VXM01, which targets VEGFR-2 for cancers such as pancreatic cancer.
Which company owns Vaximm AG?
Vaximm AG is a subsidiary of OSR Holdings, Inc.
What is the goal of Vaximm under Dr. Niethammer's leadership?
The goal is to create durable antitumor responses while ensuring safety and tolerability.
